Amphastar Pharmaceuticals Balance Sheet
NASDAQ: AMPHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Amphastar Pharmaceuticals financial position
At the end of fiscal 2025, Amphastar Pharmaceuticals reported total assets of $1.63 billion, up 3.3% from a year earlier against total liabilities of $840.5 million. Shareholders' equity stood at $788.8 million, or 48.4% of assets. The company held $170.2 million in cash and equivalents against $621.3 million of debt, a net debt position of $451.2 million.
The current ratio (current assets divided by current liabilities) was 4.02, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.79.
Summary generated from market data by MetaCap's automated system. Methodology
Amphastar Pharmaceuticals balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 170.18M | 151.61M | 144.30M | 156.10M | 126.35M | 92.64M | 73.69M | 86.34M | 65.59M | 72.35M |
| Short-Term Investments | 112.64M | 70.04M | 112.51M | 19.66M | 10.32M | 12.98M | 11.68M | 2.83M | 2.63M | 527.00K |
| Receivables | 143.56M | 136.29M | 114.94M | 88.80M | 78.80M | 66.00M | 45.38M | 52.16M | 36.00M | 26.78M |
| Inventory | 176.89M | 153.74M | 105.83M | 103.58M | 92.81M | 96.83M | 110.50M | 69.32M | 63.61M | 79.75M |
| Total Current Assets | 636.02M | 534.07M | 489.60M | 378.32M | 318.12M | 279.68M | 255.24M | 220.34M | 187.78M | 184.10M |
| Property, Plant & Equipment | 310.57M | 297.35M | 282.75M | 238.27M | 244.24M | 260.06M | 233.86M | 210.42M | 180.54M | 152.94M |
| Goodwill | 3.40M | 3.05M | 3.22M | 3.13M | 3.31M | 3.94M | 3.63M | 3.95M | 4.46M | 3.98M |
| Intangible Assets | 533.34M | 558.39M | 580.85M | 4.95M | 6.33M | 7.45M | 8.29M | 9.09M | 11.45M | 17.11M |
| Long-Term Investments | — | 11.00M | 14.69M | — | — | — | — | — | — | — |
| Total Assets | 1.63B | 1.58B | 1.51B | 741.99M | 671.53M | 631.24M | 586.97M | 513.56M | 451.07M | 427.74M |
| Accounts Payable | 32.59M | 30.51M | 25.44M | 20.50M | 22.21M | 24.36M | 25.06M | 31.32M | 16.63M | 19.93M |
| Short-Term Debt | 1.64M | 234.00K | 436.00K | 3.05M | 2.20M | 12.26M | 7.74M | 18.23M | 6.31M | 5.37M |
| Total Current Liabilities | 158.16M | 173.76M | 225.41M | 94.86M | 103.81M | 112.20M | 90.01M | 106.83M | 67.19M | 60.62M |
| Long-Term Debt | 619.71M | 613.53M | 603.17M | 76.64M | 78.19M | 45.92M | 46.32M | 49.10M | 45.72M | 36.03M |
| Total Liabilities | 840.49M | 845.17M | 873.49M | 213.33M | 226.01M | 182.51M | 159.44M | 149.20M | 117.34M | 98.48M |
| Shareholders' Equity | 788.80M | 732.30M | 639.42M | 528.66M | 445.52M | 402.31M | 381.37M | 332.44M | 333.74M | 329.25M |
| Retained Earnings | 666.88M | 568.79M | 409.27M | 271.72M | 180.34M | 117.77M | 116.37M | 67.48M | 72.64M | 70.86M |
| Total Debt | 621.35M | 613.77M | 603.61M | 79.69M | 80.39M | 58.19M | 54.06M | 67.33M | 52.04M | 41.40M |
| Net Cash (Debt) | -338.53M | -392.12M | -346.80M | 96.07M | 56.29M | 47.43M | 31.30M | 21.84M | 16.19M | 31.48M |
| Shares Outstanding | 45.65M | 47.62M | 48.07M | 48.11M | 47.71M | 47.50M | 46.58M | 46.63M | 46.62M | 46.25M |
This table shows 10 annual periods of Amphastar Pharmaceuticals's balance sheet, from FY 2025 back to FY 2016, across 20 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow AMPH's reporting calendar. What is a balance sheet?